COMPOSITION FOR ALLEVIATING, PREVENTING, OR TREATING NEURODEGENERATIVE DISEASES, COMPRISING BRASSICACEAE EXTRACT
The present invention refers to improved neurodegenerative diseases including extract [...], for preventing or treating composition is disclosed with a. Crucifera ( cross, Brassicaceae) or cabbage from is one and of firewood cross plant kernel. Four flower petal is cross copyright 2001. Cabbage and mustard of an edible crop. belonging to this classification. Provided directly to the clock inputs of which leaves that DPRAM is full is't chin leaf and manner as to deviate from one another. 200 speed 1800 paper mainly to, the comprised of a constituent of which oxidizing products, in particular temperate zoneit is born. Retinoblastoma 18 22 48 1 species into the Korean 1 variants is connected to the semiconductor layer. varieties. Nervous system includes provided to store various types of cells. Neural impact delivery of nerve cells subunit (neuron) and said neural by a cell in either the a space vacant neural a driving gear group is gear-oligodendrocyte. Alternatively or skin cells, neural cells. the additional delay, a new recovery interchangeable. Each special in function of the overall system and to therefore to be responsible for enumerating the portion of the.. Neuronal death of neuronal degeneration including depth in the dermis at which nerve structural and functional method for gradually loss.. Parkinson diseases, Alzheimer's disease and Huntington's disease including diseases many neurodegenerative diseases resulting from the consequences of a degradation process with the exception of a neuroprotective occurs. Natural extract and include patent station associated neuronal degeneration, including opening patent number 10-2002-7002061 call may be medicinal Ginseng for protecting neuronal cells or brain cell, nerve cell protecting call opening patent number 10-2010-0060949 [...] call opening patent number 10-2003-0007105 composition and containing nerve cell protecting and composition for repairing is to, include patent not become dirty, WO2012001687 A neuroprotective natural extract, such as US13/517,381 Plant extracts for treating neurodegenerative disease and PCT/GB2007/000122 Cannabinoid-containing plant extracts as neuroprotective agents. The present specification patent document and thesis plurality of throughout the citation is referred to in the. are displayed. Citation patent document and papers of learned Society in their entirety a disclosure of a specification referenced to the present invention are inserted into levels and is in the field of the contents of the present invention is described more specifically. The present inventor to improve neurodegenerative diseases are, preventing or treating [...] finding is transmitted material and to can be (microglia) which inhibit the activity of natural extract he made efforts toward being looked for. As a result, ( Therefore, the present invention refers to useful as anti- [...] improved neurodegenerative diseases including, composition for preventing or treating 410 is pulled out from the engagement. Another object and advantages of the present invention of the following detailed description of the invention, by drawing range and claimed is especially more specifically. According to one aspect of the present invention, the present invention refers to ( The present inventor to improve neurodegenerative diseases are, preventing or treating [...] finding is transmitted material and to can be (microglia) which inhibit the activity of natural extract he made efforts toward being looked for. As a result, ( Used in composition of the present invention extract [...][...] high purity and uniform particle size distribution when the which is obtained by treating, various can be used is an extraction solvent. According to an exemplary embodiment of the present invention, as said polar solvent or nonpolar extraction solvent can be solvent is regulated so as to have. The suitable as polar solvent, water (i), (ii) alcohol (of the present invention according to an exemplary embodiment, methanol, ethanol, propanol, butanol, normal-propanol, ISO-propanol, normal-butanol, 1-pentanols, 2-butoxyethanol or ethylene glycol), (iii) acetic acid, (iv) DMFO (dimethyl-formamide) and includes (v) DMSO (dimethyl sulfoxide). Suitable as a non-polar solvent with the, acetone, acetonitriles, ethyl acetate, methyl acetate, fluoro alkane, cyclopentane, hexane, 2, 2, 4-tree methyl pentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane to form a polyolefin and withdrawing, cyclopentane chloro 1-, According to an exemplary embodiment of the present invention, extracted solvent in the present invention using water (a), (b) of lower alcohols or function objects and anhydride 1-4 carbon atoms (methanol, ethanol, propanol, such as butanol), (c) said lower alcohol and/water solvent, acetone (d), (e) ethyl acetate, chloroform (f), (g) butyl acetate, (h) 1,3-butylene glycol, includes d ethyl ether (i) hexane and (j). According to an exemplary embodiment of the present invention, water extract of the present invention, methanol, or a combination of. which is obtained by treating [...]. Of the present invention according to another embodiment, of the present invention extracted from methanol extract [...][...] is extract. Terms used in the present specification 'extract' trillion extraction water in the art for the above as (crude extract) but the meanings commonly used to, the treatment of the solid type extract at light (fractionation) fraction also includes a fraction. I.e., [...] extract solvent is regulated so as to have an extractor that is described above is prepared as well as, further purification procedure herein is prepared applied also includes a. E.g., said extract of molecular weight cut-off value fraction the signal passes through filtration membrane ultrafiltration, various chromatography (size, charge, hydrophobicity or affinity for separation according to made from a) for the separation by such as, additionally a variety of embodiment a purifying method of a product that is prepared also fraction is being included in extract [...] of the present invention. In the present invention the pressure-reducing extract [...] used in the distillation and freeze-dried or spray dried this additional and the like complex feed is as by a process that can be produced. The present specification in terms' including as active ingredient ' efficacy or extract of the following rotation [...] sufficient to attain activity means a including amount of a. The present invention refers to natural plant material; and a composition extracted from [...] may administering excess human body since there is no side effects of the present invention extract quantitative included in composition [...] 6a. one skilled in the range appropriate can be selected on the embodiment. Useful as anti- [...] of the present invention including improved, and treatment compositions, can be preventing or treating. Of the present invention said neurodegenerative diseases the Alzheimer's disease, dementia, diseases Huntington's disease, Parkinson disease, amytophic lateral sclerosis, memory layer, the oxide layer and the selected from the group consisting of myasthenia Gravis is diseases. According to an exemplary embodiment of the present invention, said composition inhibit (activation) microglial activation. Composition of the present invention useful as anti- [...] including 45-65% a microglial activation, 2000 53-57% or 50-60%. Of the present invention according to an exemplary embodiment, said composition has activity (neuroprotective) neuroprotective. Of the present invention useful as anti- [...] including composition (neuron) neuronal cells to reduce microglial activation of cell death, and 10-40%, 2000 20-30% or 15-35%. According to an exemplary embodiment of the present invention, said composition. (apoptosis) apoptosis of new nerve cells. Of the present invention useful as anti- [...] including compositions 5-25% apoptosis of cells, 2000 10-20% or 8-22%. Food composition composition of the present invention, functional food composition is or pharmaceutical composition. Food composition of the present invention composition may be provided. Of the present invention useful as anti- [...] including prevention of neurodegenerative diseases, food composition for treatment or treatment when producing composition, as the active ingredient as well as extract [...], acids, are included in an amount normally arise during the production of food which contains an a, for example, protein, carbohydrate, fat, nutrient, seasoning includes flavoring and number. Waste transfer crane of nuclear power mono examples of the above-mentioned carbohydrate, for example, glucose, such as oligosaccharides; disaccharides, for example maltose, sucrose, such as oligosaccharide; and polysaccharide, for example dextrin, cyclodextrin such as sugars and a conventional processing modules, such as xylitol, sorbitol, erythro [...] is intraorally rapidly disintegrable such as. Flavor number natural flavor number [TAU Martin, Stevia extract (for example [...] A, such as [...] )] and synthetic flavor number (saccharin, such as [...] ) that is capable of using optical. E.g., abundant made of the present invention when the food composition of the present invention in addition to extract [...] citric acid, liquid oligosaccharide, sugar, glucose, acetic acid, malic acid, juice, capsules, soft capsules extract, jujube extract, licorice extract furthermore, the number of. can be contained in. Of the present invention useful as anti- [...] including prevention of neurodegenerative diseases, treatment for treatment or composition can be produced. Functional food composition of the present invention when producing composition, typically in the fabrication of food which contains an added, for example, protein, carbohydrate, fat, nutrient and seasoning includes. E.g., abundant made as the active ingredient when the flavor in addition to extract [...] number or natural carbohydrate. layer can be incorporated in additional components. For example, natural waste transfer crane of nuclear power mono the carbohydrate (e.g., glucose, fructose such as); disaccharides (e.g., maltose, such as sucrose); oligosaccharide; polysaccharide (e.g., dextrin, such as cyclodextrin); and sugar (e.g., xylitol, sorbitol, such as erythritol) includes. Flavor number flavor natural number (e.g., TAU rail, such as Stevia extract) and synthetic flavor number (e.g., saccharin, such as [...] ) can be using. Of the present invention useful as anti- [...] including prevention of neurodegenerative diseases, treatment for treatment or compositions comprise pharmaceutical compositions can be produced. The above-mentioned (a) composition of the present invention extract [...] pharmaceutically effective amount of the present invention; and (b) pharmaceutically acceptable carrier including pharmaceutical composition. The present specification in terms "pharmaceutically effective amount" the above [...] efficacy or extract an amount sufficient to attain activity.. Of the present invention composition when producing in pharmaceutical compositions, of the present invention pharmaceutical compositions comprise pharmaceutical acceptable carrier. Pharmaceutical compositions of the present invention included in a pharmaceutically acceptable carrier using normally arise during the agents is formed among the, lactose, dextrose, sucrose, sorbitol, mannitol, starch, rubber acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxy benzoate, profile hydroxy benzoate, talc, magnesium or mineral oil such as stearic, including, but, not limited to. Pharmaceutical composition of the present invention in addition to component said lubricant, wetting, sweetener, flavor number, number emulsion, suspension number, and preservatives may include further. Suitable a pharmaceutically acceptable carrier and the formulations Pharmaceutical composition of the present invention can be oral or parenteral administration. Of the present invention of pharmaceutical compositions formulated dose constitutes a suitable method, regimens, patient's age, weight, -, pathological conditions, food, administration time, route, , sensitive reaction speed and disposed to factors such as chronological age can be prescribed by.. Of the present invention of pharmaceutical compositions based on an adult individual doses, generally in the range of about kg/0.001-100 mg. The pharmaceutical composition of the present invention invention is in the field of the easily person with skill in the art in the method according to embodiment, pharmaceutically acceptable carrier and/or excipient by formulated using unit dosage form prepared or or multicomponent the ingrowth to the container in the amount can be produced. The solution in aqueous medium oil or formulation the, suspension, syrup or emulsions number X in the form or number, masked powders that are to be, powder number, number granules, tablets or capsule number which may be in the form, number or stabilizers dispersion may additionally comprise. Abstract for aspects and advantages of the present invention off at the first and the second.: (A) the present invention refers to ( (B) of the present invention a natural composition extracted from [...] side effects human body composition properties, and hardly composition. Also 1a and 1b different crucifera natural extract NO-derived LPS the mobile phone confirms the effect inhibition of occurrence of any is result. BV-2 [...] culture invitation (also 1a) or RAT 2 micro g/Ml LPS (also 1b) to the treated while coming into time 24 a each release NO effects of extract grease exhibits a blade-length-variable-reagent (griess). The cytotoxic factor have been measured by MTT assays. Average ± 3 a all users' independent times. from the standard kit article showed fiber number is compared to group '###' significant differences in the (< 0.001 p) indicates the, < 0.05 p the '*', '**' '***' < 0.01 and < 0.001 the p the p the LPS compared to group the experiments processing an indication a difference is significant. Also 2a and 2b the LPS-derived NO a WR exhibits novel compounds effective in inhibiting the extract. BV-2 [...] culture invitation (also 2a) or RAT 2 micro g/Ml LPS (also 2b) to the treated while coming into time 24 a a release NO WR. a first extract. The cytotoxic factor have been measured by MTT assays. Inhibitors iNOS L-NMMA. the control group has a positive fiber number is compared to group '###' significant differences in the (< 0.001 p) indicates the, < 0.05 p the '*', '**' '***' < 0.01 and < 0.001 the p the p the LPS compared to group the experiments processing an indication a difference is significant. Figure 3 shows a condition medium more, exhibiting by anger schedule kit article. Badge system conditions in Figure 4 for nerve cell death-mediated [...] WR extract exhibits a neuroprotective effect. MTT analysis it was determined that survival cells of SH-SY5Y. Each experiment groups configured as follows: (The control group conditions medium) Control-CM grown on the 24 time BV-2 cells the supernatant (medium) and; the LPS-CM BV-2 cell culture treated with LPS time 2 is medium conditions; the LPS-WR-CM WR time 0 cell culture BV-2 2 and culture extract treated with LPS time and medium conditions; the control-CM-LPS said treated with LPS the culture medium to which conditions the control group is medium conditions; the control-CM-WR WR the culture medium to which conditions the control group said extract has been processed (also 4a) is medium conditions. (The control group conditions medium) Control-CM grown on the 24 time BV-2 cells the supernatant (medium) and; the Aβ-CM BV-2 A β time 2 cell culture is treated with medium conditions; the Aβ-WR-CM WR time 0 cell culture BV-2 2 and culture extract treated with A β time and medium conditions; said a control-CM-Aβ A β the culture medium to which conditions the control group treated with is medium conditions; the control-CM-WR WR the culture medium to which conditions the control group said extract has been processed (also 4b) is medium conditions. Average ± 3 a all users' kit article independent times showed from the standard. '##' P in comparison with the control group untreated and value of < 0.01, a ** A β or LPS p comparing the signal-to-group processing alone has a value of a < 0.01. Anti-apoptosis effect Figure 5 WR extract more, exhibiting. 24 medium conditions-LPS SH-SY5Y a treated while coming into time of cells inhibit apoptosis-induced medium conditions. Green PI and Annexin-FITC through dyeing FACS LPS-induced apoptosis (488 nm and 633 nm excitation wavelength) it is found out that to. Also the control group has 5a, 5b also the LPS-conditions the 5c also medium and exhibits and medium conditions-extract LPS/WR. Distinguish between step apoptosis was then: initial apoptosis (Annexin+/PI-); late apoptosis/is delimited cis cells (Annexin+/PI+); and survivability of cells (Annexin-/PI-). Figure 6 shows a co-Glial cell-neural also in culture LPS or A β-oil for at killing a of new nerve cells-mediated [...] WR extract exhibits a neuroprotective effect. Raw or extract and WR cortical culture invitation RAT neural cells all A β or LPS. 24 process has been completed, MTT analysis cell survival has been confirmed. Average ± 3 a all users' kit article independent times showed from the standard. Average ± 3 a all users' kit article independent times showed from the standard. '##' P in comparison with the control group the and value of < 0.01, a ** A β or LPS p comparing the signal-to-group processing alone has a value of a < 0.01. Hereinafter, embodiment to the present invention. as further described further. These embodiment only relate more specifically, the present invention for, the present subject matter of invention embodiment range according to requirements and/or at least two of the present invention is not limited in the art that will nontrivial twiddle factors and in person with skill in the art. [...] 1 : [...] of processing for extracts of Dried [...] remove use a 80% methanol at room temperature the ultrasonic after the extracting time 2 after removing contaminants and metal oxides in methanol distillation and decompresses, freeze-drying, the third to eo. In the embodiment 2 : [...] (microglia) inhibition activity of verification Chrysanthemum and crucifera 50 of food and verifying the preventing NO extract was woman slave. with activity[...] cells (microglia) to validate the cosmetic products, BV-2 [...] NO [...] culture invitation RAT derived LPS (Lipopolysaccharide) after a process, by using a liquid upper factor have been measured by reagent (Griess) wireless glow. 10 micro g/Ml crucifera food material on upper and, 8 species extract of inhibiting the secretion NO corresponding advertisement based on the shown list it is confirmed that, [...] a mount bracket ( In the embodiment 3: preventing with activity[...][...] extract WR crucifera food extract selected to validate the suppression royal tomb active [...] extract, concentration by carrying out experiment was NO production inhibiting effect, so. As a result, by concentration extract WR (g/Ml micro 1, 10, 50) on upper and, the non-viscous coating layer is NO concentration dependent fashion significance provided to part recessed from the conductive surface. BV-2 [...] culture invitation RAT [...] 2 2 process has been completed processing extract WR micro g/Ml LPS results stimulate the into a cell, and is incremented with 23 µm BV-2 the NO in cells was 18.2 µm group out processing extract g/Ml WR micro 1,10 micro g/Ml and 9.8 µm and 15.2 µm each group processing g/Ml micro 50 50 micro g/Ml processing group out to best effects has been confirmed. [...] culture invitation RAT derive a similar results even-adsorbers could be, and is incremented with LPS was 32 µm by WR production NO 1,10 extract each group processing g/Ml micro 50 and 29.3 µm, 14.3 µm and 21.0 µm [...] culture invitation is reduced to results in a significant statistically even NO by reduce the amount of generating. The LPS NO of 56% contrast group processing exhibits reduction effect. NO with 20 cytotoxic it is caused by the not to certification results measuring a rate cell survival, WR [...] culture invitation RAT [...] BV-2 extract and do not show a slowed toxicity in a cytotoxicity is implying NO by non-inhibitors, inhibitors by WR NO efficacy 2000 (also 2). In the embodiment 4:WR [...] extract neurotoxicity protecting effect with in activity[...] a microglial secretion (neuron) the neural materials causing the extraction of the cell death of, again in neuronal cells simultaneously death of new nerve cells secretory material harmful in microglial activation is repeated neuronal cells guided the established connection continues to a wide range of temperatures. Microglial hyperactivation of control efficacy is verified a WR extract made using astrocytomas, a neural a human (conditioned media) medium conditions in (human neuroblastoma cell) cells (rat primary cultured cortical neuron) neural cortical culture invitation RAT and a SH-SY5Y applied to extract by for regulating angiogenic activity wherein [...] WR, of new nerve cells cell death, and it is found out that whether inhibitors. Microglial and the use of the cells for medium conditions shown as follows: SH-SY5Y cells 1×106 cells/Ml 24 the mixed with culture nor post-incubation time, for processing Aβ-CM or LPS-CM 16-24 by culturing time, modulating cells via MTT it was determined that for (cell viability) survival rates. When for processing LPS-CM, while represents survival of 58%, LPS extract and WR (WR/LPS-CM) medium 86% for processing conditions in that it represents a survival rates of microglial by WR of neuronal cells and regulators of human prolyl 4-hydroxylase inhibiting cell death, and it has been confirmed. Processing in addition Aβ-CM (Aβ-conditioned media) to determine if the numbers but represents cell survival of 67%, a extract and WR Aβ-CM (WR/Aβ-CM) in that it represents a survival rates of 86% WR active microglial by A β extract it has been confirmed of (also 3 and 4). In the embodiment 5:WR to neurotoxicity [...] extract anti-apoptosis efficacy Microglial active by controlling a nerve cell death inhibitors by inhibiting apoptosis (apoptosis) confirms whether to, flow cell assay (flow cytometry) using apoptosis inhibitors identified. On the first cell death by apoptosis Annexin-V and which become hydrophobic as a and cell, (necrosis) necrosis cells are physically killing, such as PI (Propidium iodide) when the to nuclear is. capable of checking. MTT of cells in a method such as a behind, embodiment results FACS analysis, in Figure 5 such as a, only medium conditions-LPS in the group processing been proceeds identification of tis apoptotic 72%, 57% in medium conditions-WR/LPS the processing activity by inhibiting the apoptosis is apoptosis of neural cells was verifying the protection efficacy. In the embodiment 6:co-Glial cell-neural extract WR in culture neurotoxicity protecting effect WR aging tread conditions extract and the extract WR microglial cells for regulating angiogenic activity wherein nerve cell death preventing verification the n bit parallel data inputted, WR extract directly of new nerve cells, and confirms whether the modulating cell death, and and produces a neuroprotective-nerve cells for the cavity-culture of an un-cross-linked (glial) cells either directly after (co-culture) WR experiment identifying system-protecting activity and extract the embodiment. Culture invitation RAT neural and cortical culture invitation RAT Glial cells grown on each days after 7-12, using (transmembrane) transmembrane on nerve cell culture using the frequency divides the nerve Glial cell co-culture-dependent preplanned, 2 micro g/Ml LPS or 25 µm A β process it was determined that cytotoxicity. As a result, 54% by LPS have been shown rate cell survival of neural cells extract processing group out g/Ml WR micro 50 79% of cell survival compared to LPS alone that it represents a rate higher by about 47% in control army identifying the n bit parallel data inputted a cell survival rates, Aβ processing group out while represents 60% of cell survival, in 50 micro g/Ml WR extract processing group than in the group processing alone A β 34% increased survival rates cell co-culture system that it represents a WR extract Glial even nerve modulate the activity of cells having for an, protects cells it has been confirmed (also 6). At least specific 360degree described in detail a portion of the present invention, homogeneously distributed such specific person with skill in the art to be only the techniques and the user makes a Yale a preferred embodiment, the of the present invention range is limited. it is apparent that the not. The-range of the present invention thus substantially manufacture the claims is defined by equivalent thereof will the pixels include. The present invention relates to a composition for alleviating, preventing or treating neurodegenerative diseases, comprising a Brassicaceae extract as an active ingredient. The composition of the present invention reduces the activation of microglial cells, has neuroprotective activity, and reduces the apoptosis of neurons. In addition, the composition extracted from Brassicaceae, which is a natural product, has little or no side effect. COPYRIGHT KIPO 2016 [...] for reducing (activation) microglial activation ( According to Claim 1, said neurodegenerative diseases the Alzheimer's disease, dementia, diseases Huntington's disease, Parkinson disease, amytophic lateral sclerosis, memory layer, the oxide layer and the selected from the group consisting of myasthenia Gravis is diseases characterized by composition. According to Claim 1, said composition characterized by that the same is provided with at active (neuroprotective) neuroprotective composition. According to Claim 1, said compositions all forms of sulfur, and decreasing (apoptosis) apoptosis of cells characterized by composition. [...] for reducing (activation) microglial activation (
